Pooled analysis of tiotropium Respimat® pharmacokinetics in cystic fibrosis

Abstract Tiotropium is the first bronchodilator to be studied systematically in cystic fibrosis (CF). We investigated whether any intrinsic or extrinsic factors affected pharmacokinetic (PK) parameters of inhaled tiotropium delivered by Respimat® in adults and children with CF. Tiotropium PK in pati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pulmonary pharmacology & therapeutics 2014-12, Vol.29 (2), p.217-223
Hauptverfasser: Sharma, Ashish, Geller, David E, Moroni-Zentgraf, Petra, Kattenbeck, Sabine, Schmid, Marion, Boland, Katja, Rapp, Barbara, Konstan, Michael W, Ratjen, Felix, Elborn, J. Stuart, Koker, Paul
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Tiotropium is the first bronchodilator to be studied systematically in cystic fibrosis (CF). We investigated whether any intrinsic or extrinsic factors affected pharmacokinetic (PK) parameters of inhaled tiotropium delivered by Respimat® in adults and children with CF. Tiotropium PK in patients with CF was compared with that of healthy volunteers and patients with chronic obstructive pulmonary disease (COPD). This pooled analysis summarizes the PK parameters of inhaled tiotropium Respimat® across 9 early- and late-phase trials involving 27 healthy volunteers (1 trial), 409 patients with CF (3 trials), and 281 patients with COPD (5 trials). Patients with CF aged 5 to 11, 12 to 17, and ≥18 years had similar tiotropium plasma concentrations (geometric mean C0.083,ss,norm : 2.22 pg/mL/μg; not determined for patients aged
ISSN:1094-5539
1522-9629
DOI:10.1016/j.pupt.2014.08.004